Clinical Characteristics and Prognosis of Allergic Bronchopulmonary Aspergillosis: A Retrospective Cohort Study
Yingying Zeng,Xiaomin Xue,Hui Cai,Guiping Zhu,Mengchan Zhu,Jian Wang,Xixi Song,Yuqing Mo,Xin Gao,Jiaye Zhou,Ling Ye,Meiling Jin
DOI: https://doi.org/10.2147/JAA.S345427
2022-01-12
Journal of Asthma and Allergy
Abstract:Yingying Zeng, 1, 2 Xiaomin Xue, 1, 2 Hui Cai, 1, 2 Guiping Zhu, 1, 2 Mengchan Zhu, 1, 2 Jian Wang, 1, 2 Xixi Song, 1, 2 Yuqing Mo, 1, 2 Xin Gao, 1, 2 Jiaye Zhou, 3 Ling Ye, 1, 2 Meiling Jin 1, 2 1 Department of Respiratory and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; 2 Department of Allergy, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; 3 Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China Correspondence: Meiling Jin; Ling Ye Department of Respiratory and Critical Care Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China Tel +86 21-64041990 Email ; Background: The clinical features, treatment, and prognosis of allergic bronchopulmonary aspergillosis (ABPA) are not well-defined. Objective: We aimed to investigate the clinical characteristics, therapy, and prognosis of ABPA to aid its clinical recognition. Methods: A total of 232 patients with ABPA were analyzed retrospectively. The characteristics of ABPA in terms of its misdiagnosis, computed tomography classification, therapy, and its relationship with asthma were analyzed, and risk factors for acute exacerbation of ABPA were analyzed based on follow-up data. Results: Of the 232 ABPA patients, 132 had a history of misdiagnosis. Compared with the misdiagnosed patients, ABPA patients with central bronchiectasis, a high total eosinophil count, and mucus plugs were less likely to be misdiagnosed. Compared with serological ABPA, ABPA with central bronchiectasis was more likely to occur in older people and in patients with mucus plugs, and decreased forced vital capacity and diffusing capacity for carbon monoxide. ABPA patients with asthma were more likely to have bronchiectasis, decreased lung function in 1 s FEV1 and FEV1/FVC, and shorter time to first acute exacerbation compared with ABPA patients without asthma. Patients receiving glucocorticoids plus antifungal therapy had a longer time to first exacerbation than those receiving glucocorticoid therapy alone. Univariate and multivariate analyses revealed that duration of asthma history, duration of misdiagnosis, mucus plugs, and poor pulmonary function were risk factors for acute exacerbation of ABPA. Conclusion: To our knowledge, this is the largest sample size study of ABPA in China. ABPA patients with a history of asthma and/or central bronchiectasis on high-resolution computed tomography are prone to frequent acute exacerbations. The use of glucocorticoids combined with antifungal drugs can prolong the time to the first acute exacerbation in ABPA patients. Longer durations of asthma history and misdiagnosis, mucus plugs, and poor pulmonary function are risk factors for acute exacerbation of ABPA. Keywords: allergic bronchopulmonary aspergillosis, central bronchiectasis, diagnosis, follow-up, treatment Allergic bronchopulmonary aspergillosis (ABPA) is a complex pulmonary disorder resulting from immune hypersensitivity to airway colonization by Aspergillus fumigatus . 1,2 The diagnosis of ABPA is based on a combination of clinical, biological and radiological manifestations and diagnosis criteria. 3,4 However, despite these diagnostic criteria, the diagnosis of ABPA remains difficult. ABPA is currently classified into five stages by the International Society for Human and Animal Mycology (ISHAM) Working Group. 3 Previous studies have shown that patients with stage I–IV ABPA can enter complete remission, but patients with stage V are more likely to develop pulmonary fibrosis, and even irreversible lung injury. However, many patients with early-stage ABPA have atypical symptoms, which could delay the diagnosis and lead to advanced disease at the time of diagnosis. The mean diagnostic delay was as long as 10 years in patients with ABPA who were eventually diagnosed correctly at later stages. The early diagnosis and treatment of ABPA are therefore required to prevent long-term lung tissue damage. The unsatisfactory management of ABPA is mainly caused by a poor understanding of the disease, and the lack of standardized treatment plans. 5 Although many cases of ABPA have been reported, there has been no large sample size study to comprehensively describe the clinical features, diagnosis, and prognosis in Chinese patients. In the present study, we analyzed 232 patients diagnosed with ABPA who su -Abstract Truncated-
immunology,allergy,respiratory system